论文部分内容阅读
目的 分析和评价肾移植后肝功能不良患者使用霉酚酸酯（ＭＭＦ） 的有效性和安全性。方法 １２ 例患者术后免疫抑制方案为：９ 例采用环孢素Ａ（ＣｓＡ） 、硫唑嘌呤（Ａｚａ）、泼尼松（Ｐｒｅｄ） ；３例采用ＣｓＡ、Ｐｒｅｄ。发生肝功能不良后， 停用Ａｚａ；９ 例采用三联治疗的患者，６ 例减少ＣｓＡ 用量１／４～１／３ ，３ 例改用ＣｓＡ、Ｐｒｅｄ；３ 例采用二联治疗者，１ 例减少ＣｓＡ 用量，２ 例停用ＣｓＡ；１２ 例均加用ＭＭＦ１ ．５ ～２．０ ｇ／ｄ。结果 １１ 例肝功能恢复正常， 无新的排斥发生。结论 ＭＭＦ是一种强有力的免疫抑制剂， 无肝、肾毒性， 移植后肝功能不良患者使用ＭＭＦ， 可停用Ａｚａ， 减少ＣｓＡ 用量， 不增加排斥的发生。
Objective To analyze and evaluate the efficacy and safety of mycophenolate mofetil (MMF) in patients with liver dysfunction after renal transplantation. Methods Twelve patients received immunosuppression after surgery: CsA, Aza and Pred were used in 9 patients and CsA, Pred in 3 patients. After the occurrence of liver dysfunction, Aza was discontinued; 9 patients treated with triple therapy, 6 patients reduced CsA dosage 1/4 ~ 1/3, 3 patients switched to CsA, Pred; CsA dosage, CsA was stopped in 2 patients and MMF1 in 12 patients. 5 ~ 2.0 g / d. Results Eleven patients returned to normal liver function without any new rejection. Conclusion MMF is a potent immunosuppressant with no hepatotoxicity and nephrotoxicity. MMF can be used in patients with liver dysfunction after transplantation. Aza can be stopped and the dosage of CsA can be decreased without increasing the incidence of rejection.